PMC:7228307 / 53179-54143
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id | tao:has_standard_notation |
---|---|---|---|---|---|---|
1088 | 3-8 | Gene | denotes | FcγRI | Gene:2214 | |
1089 | 13-20 | Gene | denotes | FcγRIIb | Gene:2213 | |
1090 | 276-280 | Gene | denotes | FcγR | Gene:2213 | |
1091 | 75-79 | Gene | denotes | FcγR | Gene:2213 | |
1092 | 578-582 | Gene | denotes | FcγR | Gene:2213 | |
1093 | 400-410 | Chemical | denotes | disulfides | MESH:D004220 | |
1094 | 36-62 | Disease | denotes | PD‐1 antibody tislelizumab | MESH:D010300 | |
1095 | 191-196 | Mutation | denotes | E233P | p.E233P | |
1096 | 198-203 | Mutation | denotes | F234V | rs755807976 | |
1097 | 205-210 | Mutation | denotes | L235A | p.L235A | |
1098 | 238-243 | Mutation | denotes | D265A | p.D265A | |
1099 | 341-346 | Mutation | denotes | S228P | rs1469294455 | |
1100 | 359-364 | Mutation | denotes | L309V | p.L309V | |
1101 | 369-374 | Mutation | denotes | R409K | p.R409K | |
1104 | 802-806 | Gene | denotes | FcγR | Gene:2213 | |
1105 | 671-675 | Gene | denotes | FcγR | Gene:2213 | |
1107 | 894-901 | Gene | denotes | FcγRIIb | Gene:2213 | |
1110 | 957-964 | Gene | denotes | FcγRIIb | Gene:2213 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T409 | 41-49 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T410 | 471-473 | Body_part | denotes | Ig | http://purl.org/sig/ont/fma/fma62871 |
T411 | 750-759 | Body_part | denotes | backbones | http://purl.org/sig/ont/fma/fma13478 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T896 | 3-5 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T897 | 13-15 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T898 | 63-66 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T899 | 75-77 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T900 | 128-132 | http://purl.obolibrary.org/obo/CLO_0007179 | denotes | L235 |
T901 | 188-189 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T902 | 268-269 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T903 | 276-278 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T904 | 305-308 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T905 | 556-557 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T906 | 578-580 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T907 | 606-616 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
T908 | 626-628 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T909 | 671-673 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T910 | 770-771 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T911 | 802-804 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T912 | 894-896 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T913 | 940-942 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T914 | 957-959 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T28 | 6-8 | Chemical | denotes | RI | http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753 |
T85014 | 36-38 | Chemical | denotes | PD | http://purl.obolibrary.org/obo/CHEBI_74756 |
T2607 | 400-410 | Chemical | denotes | disulfides | http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343 |
T70545 | 676-684 | Chemical | denotes | effector | http://purl.obolibrary.org/obo/CHEBI_35224 |
T34 | 863-871 | Chemical | denotes | effector | http://purl.obolibrary.org/obo/CHEBI_35224 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T228 | 685-694 | http://purl.obolibrary.org/obo/BFO_0000034 | denotes | functions |
T229 | 872-881 | http://purl.obolibrary.org/obo/BFO_0000034 | denotes | functions |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T59 | 400-410 | Chemical | denotes | disulfides | http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes | pubann:has_HGVS_notation |
---|---|---|---|---|---|---|
1088 | 3-8 | Gene | denotes | FcγRI | Gene:2214 | |
1089 | 13-20 | Gene | denotes | FcγRIIb | Gene:2213 | |
1090 | 276-280 | Gene | denotes | FcγR | Gene:2213 | |
1091 | 75-79 | Gene | denotes | FcγR | Gene:2213 | |
1092 | 578-582 | Gene | denotes | FcγR | Gene:2213 | |
1093 | 400-410 | Chemical | denotes | disulfides | MESH:D004220 | |
1094 | 36-62 | Disease | denotes | PD‐1 antibody tislelizumab | MESH:D010300 | |
1095 | 191-196 | Mutation | denotes | E233P | p.E233P | |
1096 | 198-203 | Mutation | denotes | F234V | rs755807976 | |
1097 | 205-210 | Mutation | denotes | L235A | p.L235A | |
1098 | 238-243 | Mutation | denotes | D265A | p.D265A | |
1099 | 341-346 | Mutation | denotes | S228P | rs1469294455 | |
1100 | 359-364 | Mutation | denotes | L309V | p.L309V | |
1101 | 369-374 | Mutation | denotes | R409K | p.R409K | |
1104 | 802-806 | Gene | denotes | FcγR | Gene:2213 | |
1105 | 671-675 | Gene | denotes | FcγR | Gene:2213 | |
1110 | 957-964 | Gene | denotes | FcγRIIb | Gene:2213 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T303 | 22-296 | Sentence | denotes | The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2. |
T304 | 297-514 | Sentence | denotes | It also has substitutions in the core hinge S228P and the CH3 L309V and R409K to stabilize the H‐chain disulfides and CH3 interactions, respectively, thereby preventing half‐Ig exchange characteristic of natural IgG4. |
T305 | 515-619 | Sentence | denotes | Collectively, these modifications create a stable IgG4 with no FcγR binding nor complement activation.17 |
T306 | 620-882 | Sentence | denotes | Thus, Fc engineering is an effective way to remove FcγR effector functions and may be preferable to using unmodified IgG2 or IgG4 backbones that have a more restricted repertoire of FcγR interactions but which are still able to induce certain effector functions. |
T307 | 884-914 | Sentence | denotes | Improving FcγRIIb interactions |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T715 | 36-40 | Protein | denotes | PD‐1 | https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3 |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T408 | 41-49 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T409 | 471-473 | Body_part | denotes | Ig | http://purl.org/sig/ont/fma/fma62871 |
T410 | 750-759 | Body_part | denotes | backbones | http://purl.org/sig/ont/fma/fma13478 |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T122 | 474-482 | http://purl.obolibrary.org/obo/GO_0015297 | denotes | exchange |
T123 | 595-616 | http://purl.obolibrary.org/obo/GO_0006956 | denotes | complement activation |
LitCovid-sample-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T122 | 474-482 | http://purl.obolibrary.org/obo/GO_0015297 | denotes | exchange |
T123 | 595-616 | http://purl.obolibrary.org/obo/GO_0006956 | denotes | complement activation |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T122 | 474-482 | http://purl.obolibrary.org/obo/GO_0015297 | denotes | exchange |
T123 | 595-616 | http://purl.obolibrary.org/obo/GO_0006956 | denotes | complement activation |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T303 | 22-296 | Sentence | denotes | The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2. |
T304 | 297-514 | Sentence | denotes | It also has substitutions in the core hinge S228P and the CH3 L309V and R409K to stabilize the H‐chain disulfides and CH3 interactions, respectively, thereby preventing half‐Ig exchange characteristic of natural IgG4. |
T305 | 515-619 | Sentence | denotes | Collectively, these modifications create a stable IgG4 with no FcγR binding nor complement activation.17 |
T306 | 620-882 | Sentence | denotes | Thus, Fc engineering is an effective way to remove FcγR effector functions and may be preferable to using unmodified IgG2 or IgG4 backbones that have a more restricted repertoire of FcγR interactions but which are still able to induce certain effector functions. |
T307 | 884-914 | Sentence | denotes | Improving FcγRIIb interactions |